Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on June 1, 2020. The registrant is a Delaware corporation with principal executive offices in Alameda, California, and its common stock is registered on the NYSE American. The filing addresses a regulatory notice regarding the company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it discloses the following financial conditions triggering the regulatory notice:
- Stockholders' Equity: Less than $2,000,000.
- Operating Performance: The company has incurred losses from continuing operations and/or net losses during its two most recent fiscal years.
- Liquidity and Debt: No specific liquidity ratios or debt obligations are detailed in this text.
Material Changes and Regulatory Status
On June 1, 2020, AgeX received a "Deficiency Letter" from the NYSE American staff indicating non-compliance with Section 1003(a)(i) of the Exchange Company Guide due to the financial metrics noted above. This represents a material change in the company's listing status, placing it at risk of delisting.
Outlook, Management Commentary, and Risks
Compliance Plan: Management intends to submit a plan to the Exchange staff by July 1, 2020, outlining actions to achieve compliance with listing standards by December 1, 2021.
Delisting Risk: There is no assurance the Exchange will accept the plan. If the plan is rejected, or if the company fails to show progress or meet standards by the December 2021 deadline, delisting proceedings will commence.
Contingency: If delisted from the NYSE American, AgeX intends to arrange for its common stock to be quoted on the OTC Bulletin Board.
Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from anticipated results due to various risk factors.
Investor Verification Checklist
- Verify the exact amount of stockholders' equity and the specific net loss figures from the two most recent fiscal years in the company's latest 10-K or 10-Q.
- Monitor the submission and acceptance status of the compliance plan by the July 1, 2020 deadline.
- Review the company's capital raising activities or strategic initiatives intended to restore equity levels above $2,000,000.
- Assess the potential impact of a transfer to the OTC Bulletin Board on stock liquidity and trading volume.